StockData
Neurocrine Biosciences Inc logo

Neurocrine Biosciences Inc (NBIX) shareholders

NBIXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 2, 2026Score 19/306% below fair value
$165.92+0.61 (+0.37%)

Close on Nov 17, 2026Market cap $16.87BP/E 24.3Yield –

Ownership

Institutional holdings as of Jun 30, 2026, from 13F filings

Held by institutions
99.5%
101M of 102M shares
Institutional holders
775
147 new, 63 sold out
Net institutional buying
2M
In Q2 2026
Insider trades, 12 months
0 buys · 50 sales
Net sold $77.43M

Shares held by institutions

Holders of more than 5%

Latest Schedule 13D (active) or 13G (passive) filed by each holder

HolderShares% of classFilingAs of
BlackRock, Inc.12,052,27112.10%13G (passive) amendmentMar 31, 2025
Dodge & Cox5,534,6245.60%13G (passive)Mar 31, 2025
JPMorgan Chase & Co.5,300,3905.20%13G (passive) amendmentSep 30, 2026
Vanguard Capital Management5,257,9415.23%13G (passive)Mar 31, 2026
Vanguard Portfolio Management5,083,5405.00%13G (passive)Sep 30, 2026

Top institutional holders

13F holdings as of Jun 30, 2026

HolderShares% of NBIXValueChange% of portfolio
BlackRock, Inc.13,711,60713.49%$2.31B+326,0000.03%
JPMorgan Chase & Co6,398,6746.29%$1.09B+956,6070.06%
Dodge & Cox5,584,7075.49%$941.22M+123,6700.49%
Vanguard Portfolio Management LLC4,974,0834.89%$838.31M+247,7390.04%
Vanguard Capital Management LLC4,545,3394.47%$766.05M+33,4350.02%
State Street Corp4,385,5984.31%$739.13M+31,0720.02%
Aqr Capital Management LLC3,818,0373.76%$643.47M−1,120,9300.22%
Renaissance Technologies LLC2,335,8972.30%$393.68M−83,0000.54%
Geode Capital Management, LLC2,138,7772.10%$359.61M+2,1050.02%
Two Sigma Investments, LP2,076,2602.04%$349.92M−984,3100.25%
Vestal Point Capital, LP1,880,0001.85%$316.85M+630,0007.40%
BNP PARIBAS ASSET MANAGEMENT Holding S.A.1,494,2591.47%$251.86M+4460.25%
Morgan Stanley1,318,6071.30%$222.23M+99,4110.01%
Rtw Investments, LP1,267,9251.25%$213.69M+205,8531.82%
Northern Trust Corp1,259,7171.24%$212.31M+16,8870.02%
Invesco Ltd.1,077,3171.06%$181.57M+721,3080.01%
Charles Schwab Investment Management Inc974,2790.96%$164.20M+71,4910.02%
Norges Bank973,8800.96%$164.13MNew0.02%
First Trust Advisors LP923,1250.91%$155.58M−36,0920.09%
Dimensional Fund Advisors LP732,8770.72%$123.53M+21,1150.02%

Institutional buying and selling by quarter

Positions opened, added to, reduced and closed by 13F filers

QuarterHoldersShares held% of sharesNew / addedReduced / closedShares boughtShares sold
Q2 2026775101M99.5%147 / 321225 / 6313M11M
Q1 2026699100M98.5%84 / 306216 / 11024M13M
Q4 202573299M97.7%139 / 275224 / 4111M13M
Q3 2025650102M100.0%121 / 220219 / 5012M10M
Q2 202558699M97.5%78 / 223221 / 7014M11M
Q1 202558696M94.8%75 / 187254 / 8313M11M
Q4 202460195M93.3%113 / 214211 / 7413M12M
Q3 202457695M93.2%71 / 236202 / 8423M11M
Q2 202459596M94.9%80 / 254189 / 689M13M
Q1 2024589100M98.8%90 / 227208 / 4911M7M
Q4 202355597M95.3%94 / 206199 / 4314M9M
Q3 202351292M90.4%90 / 159197 / 3010M8M

Top mutual fund and ETF holders

Latest monthly portfolio reports (Form N-PORT)

635 funds held NBIX in Q2 2026, 54% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.

FundShares% of NBIXValue% of fundAs of
Dodge & Cox Stock Fund3,964,0003.90%$668.07M0.56%Jun 30, 2026
iShares Core S&P Mid-Cap ETF3,441,0373.39%$579.94M0.47%Jun 30, 2026
Vanguard Total Stock Market Index Fund3,193,2673.14%$538.18M0.02%Jun 30, 2026
Vanguard Small-Cap Index Fund2,304,9962.27%$388.47M0.21%Jun 30, 2026
JPMorgan Growth Advantage Fund1,358,4751.34%$228.95M1.02%Jun 30, 2026
Vanguard Small-Cap Growth Index Fund1,329,8291.31%$224.12M0.48%Jun 30, 2026
Vanguard Extended Market Index Fund1,152,8251.13%$194.29M0.20%Jun 30, 2026
JPMorgan Mid Cap Growth Fund1,116,6741.10%$188.20M1.42%Jun 30, 2026
iShares Biotechnology ETF700,0510.69%$117.98M1.30%Jun 30, 2026
Vanguard Explorer Fund637,6140.63%$106.35M0.48%Jul 31, 2026
State Street(R) SPDR(R) S&P(R) Biotech ETF618,9660.61%$104.32M0.97%Jun 30, 2026
iShares S&P Mid-Cap 400 Growth ETF601,5190.59%$101.38M0.90%Jun 30, 2026
Invesco S&P MidCap Quality ETF599,8290.59%$100.05M1.84%Jul 31, 2026
First Trust NYSE Arca Biotechnology Index Fund588,8470.58%$99.24M3.53%Jun 30, 2026
iShares MSCI USA Min Vol Factor ETF527,7820.52%$88.03M0.37%Jul 31, 2026

Officers, directors and major owners

People who filed Forms 3, 4 or 5 in the last two years

NameRoleShares owned% of sharesLatest filing
Kyle GanoChief Executive Officer, Director155,0100.15%Nov 3, 2026
Eiry RobertsChief Medical Officer51,3310.05%Nov 5, 2026
Ingrid DelaetChief Regulatory Officer18,2890.02%Sep 15, 2026
Darin LippoldtChief Legal Officer59,2120.06%Sep 15, 2026
Eric BenevichChief Commercial Officer67,2970.07%Sep 15, 2026
Sanjay Chandru KeswaniChief Medical Officer5,3930.01%Sep 15, 2026
Jude OnyiaChief Scientific Officer22,6470.02%Sep 15, 2026
Matt AbernethyChief Financial Officer42,8080.04%Sep 15, 2026
Julie CookeChief Human Resources Officer24,0250.02%Sep 15, 2026
David W. BoyerChief Corp. Affairs Officer8,7220.01%Sep 15, 2026
Andrew RatzChief Technical Operations Off1,0180.00%Mar 17, 2026
George J. MorrowDirector10,3860.01%Nov 3, 2026
Kevin Charles GormanDirector517,7970.51%Sep 15, 2026
Stephen A. SherwinDirector14,8600.01%Sep 3, 2026
Leslie V. NorwalkDirector2,4300.00%Jul 30, 2026
Johanna MercierDirector6,8530.01%May 29, 2026
Christine A. PoonDirector4,7530.00%May 29, 2026
Shalini SharpDirector4,0880.00%May 29, 2026
Gary A. LyonsDirector122,1410.12%May 29, 2026
Richard F. PopsDirector37,7980.04%May 29, 2026
William H. RastetterDirector43,6780.04%May 29, 2026

Insider trades

Common stock transactions reported on Form 4, newest first

InsiderDateTransactionSharesPriceValueShares after
George J. Morrow
Director
Nov 3, 2026Sale(10b5-1 plan)−1,300$168.53$219.09K10,386
George J. Morrow
Director
Nov 3, 2026Sale(10b5-1 plan)−1,500$167.72$251.59K11,686
George J. Morrow
Director
Nov 3, 2026Sale(10b5-1 plan)−1,466$166.77$244.49K13,186
George J. Morrow
Director
Nov 3, 2026Sale(10b5-1 plan)−908$165.71$150.46K14,652
George J. Morrow
Director
Nov 3, 2026Sale(10b5-1 plan)−1,226$164.74$201.97K15,560
George J. Morrow
Director
Nov 3, 2026Sale(10b5-1 plan)−600$163.71$98.22K16,786
George J. Morrow
Director
Nov 3, 2026Sale(10b5-1 plan)−100$162.05$16.21K17,386
George J. Morrow
Director
Nov 3, 2026Sale(10b5-1 plan)−100$158.18$15.82K17,486
George J. Morrow
Director
Nov 3, 2026Option exercise+7,200$53.64$386.21K17,586
George J. Morrow
Director
Nov 2, 2026Sale(10b5-1 plan)−1,300$146.76$190.78K10,386
George J. Morrow
Director
Nov 2, 2026Sale(10b5-1 plan)−4,300$145.86$627.19K11,686
George J. Morrow
Director
Nov 2, 2026Sale(10b5-1 plan)−1,900$144.98$275.45K15,986
George J. Morrow
Director
Nov 2, 2026Option exercise+7,500$53.64$402.30K17,886
Kyle Gano
Chief Executive Officer, Director
Nov 1, 2026Tax withholding−332$146.10$48.51K155,010
Kyle Gano
Chief Executive Officer, Director
Nov 1, 2026Option exercise+614––155,342
George J. Morrow
Director
Oct 30, 2026Sale(10b5-1 plan)−300$149.00$44.70K10,386
George J. Morrow
Director
Oct 30, 2026Option exercise+300$53.64$16.09K10,686
David W. Boyer
Chief Corp. Affairs Officer
Sep 14, 2026Sale(10b5-1 plan)−826$157.45$130.05K8,722
Matt Abernethy
Chief Financial Officer
Sep 14, 2026Sale(10b5-1 plan)−2,311$157.20$363.29K42,808
David W. Boyer
Chief Corp. Affairs Officer
Sep 11, 2026Award+3,587––11,484
David W. Boyer
Chief Corp. Affairs Officer
Sep 11, 2026Tax withholding−1,936$156.22$302.44K9,548
Eric Benevich
Chief Commercial Officer
Sep 11, 2026Tax withholding−3,386$156.22$528.96K67,297
Eric Benevich
Chief Commercial Officer
Sep 11, 2026Award+6,275––70,683
Matt Abernethy
Chief Financial Officer
Sep 11, 2026Award+5,020––47,828
Matt Abernethy
Chief Financial Officer
Sep 11, 2026Tax withholding−2,709$156.22$423.20K45,119
Julie Cooke
Chief Human Resources Officer
Sep 11, 2026Tax withholding−1,936$156.22$302.44K24,025
Julie Cooke
Chief Human Resources Officer
Sep 11, 2026Award+3,587––25,961
Jude Onyia
Chief Scientific Officer
Sep 11, 2026Tax withholding−1,936$156.22$302.44K22,647
Jude Onyia
Chief Scientific Officer
Sep 11, 2026Award+3,587––24,583
Kyle Gano
Chief Executive Officer, Director
Sep 11, 2026Tax withholding−3,386$156.22$528.96K153,880
Kyle Gano
Chief Executive Officer, Director
Sep 11, 2026Tax withholding−994$156.22$155.28K154,728
Kyle Gano
Chief Executive Officer, Director
Sep 11, 2026Award+1,842––155,722
Kyle Gano
Chief Executive Officer, Director
Sep 11, 2026Award+6,275––157,266
Sanjay Chandru Keswani
Chief Medical Officer
Sep 11, 2026Award+3,914––5,393
Sanjay Chandru Keswani
Chief Medical Officer
Sep 11, 2026Tax withholding−2,112$156.22$329.94K3,281
Kevin Charles Gorman
Director
Sep 11, 2026Tax withholding−7,839$156.22$1.22M517,797
Kevin Charles Gorman
Director
Sep 11, 2026Award+14,343––525,636
Darin Lippoldt
Chief Legal Officer
Sep 11, 2026Award+4,483––59,212
Darin Lippoldt
Chief Legal Officer
Sep 11, 2026Tax withholding−2,419$156.22$377.90K56,793
Ingrid Delaet
Chief Regulatory Officer
Sep 11, 2026Tax withholding−2,419$156.22$377.90K18,289
Ingrid Delaet
Chief Regulatory Officer
Sep 11, 2026Award+4,483––20,708
Eric Benevich
Chief Commercial Officer
Sep 9, 2026Sale(10b5-1 plan)−2,154$154.61$333.03K64,408
Eric Benevich
Chief Commercial Officer
Sep 9, 2026Option exercise+3,194$43.24$138.11K66,562
Stephen A. Sherwin
Director
Sep 2, 2026Gift−1,000––14,860
Jude Onyia
Chief Scientific Officer
Aug 4, 2026Gift−2,409––20,996
Leslie V. Norwalk
Director
Jul 29, 2026Option exercise+842$139.43$117.40K2,430
Leslie V. Norwalk
Director
Jul 28, 2026Sale(10b5-1 plan)−1,250$182.01$227.51K1,588
Ingrid Delaet
Chief Regulatory Officer
Jul 10, 2026Sale(10b5-1 plan)−4,367$181.02$790.51K16,225
Ingrid Delaet
Chief Regulatory Officer
Jul 10, 2026Option exercise+4,367$106.02$462.99K20,592
Darin Lippoldt
Chief Legal Officer
Jul 9, 2026Sale(10b5-1 plan)−10,000$179.60$1.80M54,729
Darin Lippoldt
Chief Legal Officer
Jul 9, 2026Option exercise+10,000$81.49$814.90K64,729
Ingrid Delaet
Chief Regulatory Officer
Jul 9, 2026Sale(10b5-1 plan)−8,433$178.72$1.51M16,225
Ingrid Delaet
Chief Regulatory Officer
Jul 9, 2026Option exercise+8,433$103.52$872.98K24,658
Ingrid Delaet
Chief Regulatory Officer
Jul 8, 2026Option exercise+2,737$103.52$283.33K18,962
Ingrid Delaet
Chief Regulatory Officer
Jul 8, 2026Sale(10b5-1 plan)−2,737$178.54$488.66K16,225
Ingrid Delaet
Chief Regulatory Officer
Jul 7, 2026Sale(10b5-1 plan)−3,401$178.57$607.32K16,225
Ingrid Delaet
Chief Regulatory Officer
Jul 7, 2026Option exercise+3,401$103.52$352.07K19,626
Darin Lippoldt
Chief Legal Officer
Jun 29, 2026Sale(10b5-1 plan)−8,110$170.03$1.38M54,729
Darin Lippoldt
Chief Legal Officer
Jun 29, 2026Option exercise+8,110$81.49$660.88K62,839
Darin Lippoldt
Chief Legal Officer
Jun 29, 2026Sale(10b5-1 plan)−1,690$170.81$288.67K54,729

Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.

Short interest

Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)

Short % of float
5.88%
6M shares short
Days to cover
5.4
At 1M shares a day
Change since last report
-8.5%
From 6M shares
Short volume, 20 days
55.5%
Of volume reported to FINRA

Shares sold short, last 12 months

Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Neurocrine Biosciences's stock actually held short. Settlement fails (shares not delivered on time) peaked at 18,292 shares on Oct 2, 2026 over the last 90 days.

Planned insider sales

Notices of proposed sale filed on Form 144 before shares are sold

SellerFiledSharesMarket valuePlanned saleAcquired through
Sanjay Chandru Keswani
Former Affiliate
Nov 10, 202653,614$8.97MNov 10, 2026Exercise of Options Under a Registered Plan
George J. Morrow
Director
Nov 2, 202614,700$2.15MNov 2, 2026Exercise of Stock Options
George J. Morrow
Director
Oct 30, 2026300$43.91KOct 30, 2026Exercise of Stock Options
David W. Boyer
Officer
Sep 14, 20264,714$736.42KSep 14, 2026Restricted and Performance Stock Units
Matthew C Abernethy
Officer
Sep 14, 20262,311$361.02KSep 14, 2026Performance Stock Units
Eric Benevich
Officer
Sep 9, 20262,154$334.15KSep 9, 2026Exercise of Stock Options
Ingrid Delaet
Officer
Jul 10, 20264,367$788.46KJul 10, 2026Exercise of Stock Options
Darin Lippoldt
Officer
Jul 9, 202610,000$1.78MJul 9, 2026Exercise of Stock Options
Ingrid Delaet
Officer
Jul 7, 202614,571$2.54MJul 7, 2026Exercise of Stock Options
Darin Lippoldt
Officer
Jun 29, 20269,800$1.65MJun 29, 2026Exercise of Stock Options
Darin Lippoldt
Officer
Jun 26, 2026200$32.84KJun 26, 2026Exercise of Stock Options
Stephen A. Sherwin
Director
Jun 5, 202625,000$4.18MJun 5, 2026Exercise of Stock Options
Julie Cooke
Officer
Jun 2, 202636,937$5.95MJun 2, 2026Exercise of Stock Options
Jude Onyia
Officer
Jun 1, 202611,000$1.74MJun 1, 2026Exercise of Stock Options
Ingrid Delaet
Officer
May 29, 20262,261$353.60KMay 29, 2026Exercise of Stock Options

Congress trades

2 trades in Neurocrine Biosciences reported by 1 member of the House

MemberTypeTradedAmountFiled
Lisa McClain
MI09 · spouse
Sold (part)Jun 17, 2025$1K–15KAug 13, 2025
57 days late
Lisa McClain
MI09 · spouse
BoughtJun 11, 2025$1K–15KAug 13, 2025
63 days late

See a number that looks wrong?